"T-Lymphocytes, Cytotoxic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Descriptor ID |
D013602
|
MeSH Number(s) |
A11.118.637.555.283.875 A11.118.637.555.567.550.500.200 A11.118.637.555.567.569.220.200 A11.118.637.555.567.569.500.200 A15.145.229.637.555.283.875 A15.145.229.637.555.567.550.500.200 A15.145.229.637.555.567.569.220.200 A15.145.229.637.555.567.569.500.200 A15.382.490.555.283.875 A15.382.490.555.567.550.500.200 A15.382.490.555.567.569.220.200 A15.382.490.555.567.569.500.200
|
Concept/Terms |
T-Lymphocytes, Cytotoxic- T-Lymphocytes, Cytotoxic
- Cytotoxic T-Lymphocyte
- T Lymphocytes, Cytotoxic
- T-Lymphocyte, Cytotoxic
- Cell-Mediated Lympholytic Cells
- Cell Mediated Lympholytic Cells
- Cell, Cell-Mediated Lympholytic
- Cell-Mediated Lympholytic Cell
- Cells, Cell-Mediated Lympholytic
- Lympholytic Cell, Cell-Mediated
- Lympholytic Cells, Cell-Mediated
- Cytotoxic T-Lymphocytes
- Cytotoxic T Lymphocytes
TC2 Cells- TC2 Cells
- Cell, TC2
- Cells, TC2
- TC2 Cell
TC1 Cells- TC1 Cells
- Cell, TC1
- Cells, TC1
- TC1 Cell
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes, Cytotoxic".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Cytokine-Induced Killer Cells [A11.118.637.555.283]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.283.875]
- Lymphocytes [A11.118.637.555.567]
- Lymphocyte Subsets [A11.118.637.555.567.550]
- T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.550.500.200]
- T-Lymphocytes [A11.118.637.555.567.569]
- CD8-Positive T-Lymphocytes [A11.118.637.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.220.200]
- T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.500.200]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Cytokine-Induced Killer Cells [A15.145.229.637.555.283]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.283.875]
- Lymphocytes [A15.145.229.637.555.567]
- Lymphocyte Subsets [A15.145.229.637.555.567.550]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.550.500.200]
- T-Lymphocytes [A15.145.229.637.555.567.569]
- CD8-Positive T-Lymphocytes [A15.145.229.637.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.220.200]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.500.200]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Cytokine-Induced Killer Cells [A15.382.490.555.283]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.283.875]
- Lymphocytes [A15.382.490.555.567]
- Lymphocyte Subsets [A15.382.490.555.567.550]
- T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.550.500.200]
- T-Lymphocytes [A15.382.490.555.567.569]
- CD8-Positive T-Lymphocytes [A15.382.490.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.220.200]
- T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.500.200]
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes, Cytotoxic".
This graph shows the total number of publications written about "T-Lymphocytes, Cytotoxic" by people in this website by year, and whether "T-Lymphocytes, Cytotoxic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 2 | 6 |
1995 | 6 | 2 | 8 |
1996 | 8 | 6 | 14 |
1997 | 7 | 4 | 11 |
1998 | 14 | 10 | 24 |
1999 | 6 | 6 | 12 |
2000 | 9 | 7 | 16 |
2001 | 12 | 14 | 26 |
2002 | 8 | 10 | 18 |
2003 | 12 | 8 | 20 |
2004 | 13 | 8 | 21 |
2005 | 7 | 6 | 13 |
2006 | 9 | 9 | 18 |
2007 | 10 | 8 | 18 |
2008 | 14 | 10 | 24 |
2009 | 9 | 5 | 14 |
2010 | 22 | 7 | 29 |
2011 | 11 | 10 | 21 |
2012 | 12 | 7 | 19 |
2013 | 9 | 5 | 14 |
2014 | 8 | 5 | 13 |
2015 | 3 | 2 | 5 |
2016 | 5 | 8 | 13 |
2017 | 7 | 4 | 11 |
2018 | 5 | 5 | 10 |
2019 | 4 | 2 | 6 |
2020 | 2 | 6 | 8 |
2021 | 6 | 5 | 11 |
2022 | 2 | 2 | 4 |
2023 | 1 | 3 | 4 |
2024 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "T-Lymphocytes, Cytotoxic" by people in Profiles.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
Identification of a Clade-Specific HLA-C*03:02 CTL Epitope GY9 Derived from the HIV-1 p17 Matrix Protein. Int J Mol Sci. 2024 Sep 06; 25(17).
-
LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness. Nat Commun. 2024 Aug 27; 15(1):7366.
-
Ultra-pH-sensitive nanoparticle of gambogenic acid for tumor targeting therapy via anti-vascular strategy plus immunotherapy. Int J Pharm. 2024 Jul 20; 660:124303.
-
Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas. Nat Commun. 2024 Mar 20; 15(1):2498.
-
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-?B Signaling in Patients with Pancreatic Cancer. Clin Cancer Res. 2024 02 01; 30(3):542-553.
-
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? Eur J Cancer. 2024 Feb; 198:113501.
-
Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. J Clin Invest. 2023 09 01; 133(17).
-
Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity. Cancer Res Commun. 2023 06; 3(6):1118-1131.
-
Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of?Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol. 2023 01; 36(1):100028.